Thelansis’s “Metastatic Pancreatic Adenocarcinoma (mPDAC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Metastatic pancreatic adenocarcinoma (mPDAC) remains one of oncology's most difficult cancers, with activating KRAS mutations serving as the dominant oncogenic driver in most cases and historically offering few directly targetable options. That paradigm changed in 2026 with daraxonrasib, the first FDA-approved RAS-targeted therapy for mPDAC. The oral RAS(ON) multi-selective inhibitor significantly extended survival in previously treated patients in the Phase 3 RASolute 302 trial, with median overall survival of 13.2 months versus 6.7 months with physician's-choice chemotherapy, while also showing fewer grade ≥3 treatment-related adverse events. Its approval on August 26, 2026, marked a major milestone for a pathway long considered difficult to drug. The competitive pipeline is now diversifying further, with broad RAS inhibitors alongside mutation-specific approaches targeting variants such as KRAS G12D, including multiple programs advancing into Phase 3 trials. For stakeholders, mPDAC illustrates how advances in drug design can convert a historically elusive oncogenic pathway into a commercially actionable therapeutic class.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Metastatic Pancreatic Adenocarcinoma (mPDAC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Metastatic Pancreatic Adenocarcinoma (mPDAC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.